Goldman Sachs Initiates Buy on Corvus with $40 Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CRVS?
Source: seekingalpha
- Goldman Coverage Launch: Goldman Sachs has initiated coverage on Corvus Pharmaceuticals (CRVS) with a Buy rating and a $40 price target, with analyst Paul Choi highlighting the pipeline potential of its lead candidate, soquelitinib, which is expected to drive stock price appreciation.
- Strong Stock Performance: CRVS shares have surged over 400% in the past 12 months, reflecting strong market confidence in the company's future, particularly as the current valuation does not fully capture soquelitinib's potential in treating atopic dermatitis and other autoimmune conditions.
- Clinical Trial Catalysts: The analyst noted that soquelitinib's development for atopic dermatitis is significant, with multiple clinical trial catalysts scheduled over the next 12-18 months, which could further propel the stock price upward.
- Long-Term Growth Potential: Although soquelitinib is still in early development, the analyst envisions CRVS gradually maturing into a large-cap biotech company, as market demand for next-gen therapies continues to expand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRVS
Wall Street analysts forecast CRVS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.040
Low
11.00
Averages
13.33
High
16.00
Current: 15.040
Low
11.00
Averages
13.33
High
16.00
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Goldman Sachs Initiates Buy on Corvus with $40 Target
- Goldman Coverage Launch: Goldman Sachs has initiated coverage on Corvus Pharmaceuticals (CRVS) with a Buy rating and a $40 price target, with analyst Paul Choi highlighting the pipeline potential of its lead candidate, soquelitinib, which is expected to drive stock price appreciation.
- Strong Stock Performance: CRVS shares have surged over 400% in the past 12 months, reflecting strong market confidence in the company's future, particularly as the current valuation does not fully capture soquelitinib's potential in treating atopic dermatitis and other autoimmune conditions.
- Clinical Trial Catalysts: The analyst noted that soquelitinib's development for atopic dermatitis is significant, with multiple clinical trial catalysts scheduled over the next 12-18 months, which could further propel the stock price upward.
- Long-Term Growth Potential: Although soquelitinib is still in early development, the analyst envisions CRVS gradually maturing into a large-cap biotech company, as market demand for next-gen therapies continues to expand.
See More
Goldman Sachs Bullish on Corvus Pharmaceuticals Stock Outlook
- Goldman Sachs Rating Boost: Goldman Sachs initiates coverage of Corvus Pharmaceuticals with a buy rating and sets a $40 price target, implying a 166% upside from Thursday's close, reflecting strong market confidence in the company's new drug potential.
- Stock Price Surge: Following Goldman Sachs' report, Corvus Pharmaceuticals' stock rose approximately 9%, indicating investor enthusiasm for its new oral medication soquelitinib, which is expected to address a significant market need.
- Strong Market Demand: The global market for moderate-to-severe atopic dermatitis treatments is projected to exceed $24 billion by 2035, highlighting Corvus Pharmaceuticals' strategic positioning in this rapidly growing sector, especially as demand for non-steroidal therapies increases.
- Clinical Trial Success: Soquelitinib demonstrated positive effects in 75% of participants during early-stage clinical trials, showcasing its significant efficacy in a competitive dermatological treatment landscape, further solidifying Goldman Sachs' bullish outlook on the stock.
See More
Latest Ratings and Outlook from Wall Street
- Apple Maintained as Buy: Bank of America reiterated its buy rating on Apple (AAPL), labeling it as the “highest quality name,” and despite underperformance year-to-date, it is still viewed as a high-quality compounder supported by resilient services growth and a healthy product cycle.
- Semiconductor Sector Pressure: Mizuho downgraded NXP Semiconductors (NXPI) to sell, citing its significant exposure to the auto sector as a headwind, with the 2026 auto outlook softened by geopolitical and macroeconomic challenges.
- Netflix's Solid Performance: Bank of America reaffirmed its buy rating on Netflix following a solid first quarter that modestly beat forecasts, with management reiterating three core priorities that align with their ongoing strategic focus and competitive positioning in the market.
- Petrobras Rating Upgrade: Bank of America upgraded Petrobras (PBR) from neutral to buy, highlighting its robust cash flow generation and low double-digit dividend yield, which reduces the risk of a potential revision to its dividend policy in a high oil price environment.
See More
CORVUS PHARMACEUTICALS: OPPENHEIMER INCREASES TARGET PRICE TO $33, UP FROM $32
Company Overview: Corvus Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for cancer treatment.
Stock Price Update: The company has raised its price target from $32 to $33, indicating a positive outlook for its stock performance.
See More
Corvus (CRVS) Q4 2025 Earnings Call Transcript
See More
Corvus Pharmaceuticals Q4 2025 Earnings Call Insights
- Increased R&D Expenses: Corvus reported $9.9 million in R&D expenses for Q4 2025, driven by higher clinical trial and manufacturing costs for soquelitinib, alongside rising personnel costs, which exerted pressure on the company's financials.
- Improved Cash Position: As of December 31, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $56.8 million, up from $52 million in 2024, indicating enhanced cash flow post-financing, expected to support operations into Q2 2028.
- Significant Clinical Progress: CEO Richard Miller highlighted soquelitinib's potential in atopic dermatitis and T-cell lymphoma, particularly noting a 72% mean reduction in EASI scores in the Phase I atopic dermatitis trial, demonstrating significant efficacy that could strengthen future market positioning.
- Optimistic Future Outlook: The company plans to initiate Phase II trials for hidradenitis suppurativa and asthma in 2026, with Phase II atopic dermatitis data expected in mid-2027, reflecting strong confidence in new therapies and positive market prospects.
See More
Goldman Sachs Initiates Buy on Corvus with $40 Target
- Goldman Coverage Launch: Goldman Sachs has initiated coverage on Corvus Pharmaceuticals (CRVS) with a Buy rating and a $40 price target, with analyst Paul Choi highlighting the pipeline potential of its lead candidate, soquelitinib, which is expected to drive stock price appreciation.
- Strong Stock Performance: CRVS shares have surged over 400% in the past 12 months, reflecting strong market confidence in the company's future, particularly as the current valuation does not fully capture soquelitinib's potential in treating atopic dermatitis and other autoimmune conditions.
- Clinical Trial Catalysts: The analyst noted that soquelitinib's development for atopic dermatitis is significant, with multiple clinical trial catalysts scheduled over the next 12-18 months, which could further propel the stock price upward.
- Long-Term Growth Potential: Although soquelitinib is still in early development, the analyst envisions CRVS gradually maturing into a large-cap biotech company, as market demand for next-gen therapies continues to expand.
See More
Goldman Sachs Bullish on Corvus Pharmaceuticals Stock Outlook
- Goldman Sachs Rating Boost: Goldman Sachs initiates coverage of Corvus Pharmaceuticals with a buy rating and sets a $40 price target, implying a 166% upside from Thursday's close, reflecting strong market confidence in the company's new drug potential.
- Stock Price Surge: Following Goldman Sachs' report, Corvus Pharmaceuticals' stock rose approximately 9%, indicating investor enthusiasm for its new oral medication soquelitinib, which is expected to address a significant market need.
- Strong Market Demand: The global market for moderate-to-severe atopic dermatitis treatments is projected to exceed $24 billion by 2035, highlighting Corvus Pharmaceuticals' strategic positioning in this rapidly growing sector, especially as demand for non-steroidal therapies increases.
- Clinical Trial Success: Soquelitinib demonstrated positive effects in 75% of participants during early-stage clinical trials, showcasing its significant efficacy in a competitive dermatological treatment landscape, further solidifying Goldman Sachs' bullish outlook on the stock.
See More
Latest Ratings and Outlook from Wall Street
- Apple Maintained as Buy: Bank of America reiterated its buy rating on Apple (AAPL), labeling it as the “highest quality name,” and despite underperformance year-to-date, it is still viewed as a high-quality compounder supported by resilient services growth and a healthy product cycle.
- Semiconductor Sector Pressure: Mizuho downgraded NXP Semiconductors (NXPI) to sell, citing its significant exposure to the auto sector as a headwind, with the 2026 auto outlook softened by geopolitical and macroeconomic challenges.
- Netflix's Solid Performance: Bank of America reaffirmed its buy rating on Netflix following a solid first quarter that modestly beat forecasts, with management reiterating three core priorities that align with their ongoing strategic focus and competitive positioning in the market.
- Petrobras Rating Upgrade: Bank of America upgraded Petrobras (PBR) from neutral to buy, highlighting its robust cash flow generation and low double-digit dividend yield, which reduces the risk of a potential revision to its dividend policy in a high oil price environment.
See More
CORVUS PHARMACEUTICALS: OPPENHEIMER INCREASES TARGET PRICE TO $33, UP FROM $32
Company Overview: Corvus Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for cancer treatment.
Stock Price Update: The company has raised its price target from $32 to $33, indicating a positive outlook for its stock performance.
See More
Corvus (CRVS) Q4 2025 Earnings Call Transcript
See More
Corvus Pharmaceuticals Q4 2025 Earnings Call Insights
- Increased R&D Expenses: Corvus reported $9.9 million in R&D expenses for Q4 2025, driven by higher clinical trial and manufacturing costs for soquelitinib, alongside rising personnel costs, which exerted pressure on the company's financials.
- Improved Cash Position: As of December 31, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $56.8 million, up from $52 million in 2024, indicating enhanced cash flow post-financing, expected to support operations into Q2 2028.
- Significant Clinical Progress: CEO Richard Miller highlighted soquelitinib's potential in atopic dermatitis and T-cell lymphoma, particularly noting a 72% mean reduction in EASI scores in the Phase I atopic dermatitis trial, demonstrating significant efficacy that could strengthen future market positioning.
- Optimistic Future Outlook: The company plans to initiate Phase II trials for hidradenitis suppurativa and asthma in 2026, with Phase II atopic dermatitis data expected in mid-2027, reflecting strong confidence in new therapies and positive market prospects.
See More
